Full Breakdown
Tech Entrepreneur Develops Personalized mRNA Vaccine for Dog's Cancer
3/18/2026, 10:58:47 PM
Innovative Approach to Canine Cancer Treatment
In a groundbreaking case, Australian tech entrepreneur Paul Conyngham has developed a personalized mRNA vaccine for his eight-year-old dog, Rosie, who was diagnosed with advanced mast cell cancer. After conventional treatments, including chemotherapy, failed to yield significant results, Conyngham turned to artificial intelligence, specifically ChatGPT, to explore alternative solutions. This innovative approach has not only provided hope for Rosie but also raised questions about the potential for similar treatments in human cancer therapies.
The Development Process
Conyngham, who has 17 years of experience in machine learning and data analysis, initiated the process by using ChatGPT to identify possible treatments for Rosie's condition. Following the chatbot's suggestion, he collaborated with the UNSW Ramaciotti Centre for Genomics to sequence Rosie's DNA, which cost approximately $3,000. This sequencing allowed researchers to profile the tumor and identify mutations contributing to the cancer.
With the genetic data in hand, Conyngham worked alongside Páll Thordarson, director of the UNSW RNA Institute, to create a custom mRNA vaccine. The vaccine was designed to target the specific mutations found in Rosie's tumor. Despite facing challenges in obtaining ethics approval for the treatment, which took three months to finalize, the vaccine was eventually delivered to Rosie in December 2025.
Treatment Results and Ongoing Research
The results of the treatment have been promising. Within weeks of receiving the vaccine, one of Rosie's tumors shrank by approximately 50%, and her overall health and energy levels improved significantly. Conyngham noted, “I’m under no illusion that this is a cure, but I do believe this treatment has bought Rosie significantly more time and quality of life.” Researchers involved in the project expressed astonishment at the results, with Martin Smith, an associate professor at UNSW, stating, “It raises the question, if we can do this for a dog, why aren’t we rolling this out to all humans with cancer?”
Criticism and Caution
While the success of Rosie's treatment has garnered attention, some experts caution against overhyping the results. Biomedical engineer Patrick Heiser remarked that while creating a single mRNA vaccine is not particularly difficult, the broader implications and efficacy of such treatments require further validation. He emphasized the need for rigorous scientific proof before drawing conclusions about the treatment's effectiveness.
Future Implications
Conyngham is currently working on a second vaccine aimed at another tumor that did not respond to the initial treatment. This ongoing research highlights the potential for personalized mRNA therapies not only for pets but also for human patients. Thordarson noted that this approach could pave the way for advanced RNA-based treatments for various conditions, including neurological diseases.
As the project progresses, it underscores the bond between Conyngham and Rosie, motivating him to explore every possible avenue to improve her health. The success of this case may inspire further advancements in cancer treatment, potentially transforming how both animals and humans are treated for cancer in the future.
